Jiang Fan, Drummond Grant R, Dusting Gregory J
Howard Florey Institute, University of Melbourne, Victoria, Australia.
Endothelium. 2004 Mar-Apr;11(2):79-88. doi: 10.1080/10623320490482600.
There is growing evidence that oxidative stress, meaning an excessive production of reactive oxygen and nitrogen species, underlies many forms of cardiovascular disease. The major source of oxidative stress in the artery wall is an NADPH oxidase. This enzyme complex in vascular cells, including endothelium, differs from that in phagocytic leucocytes in both biochemical structure and functions. The crucial flavin-containing catalytic subunits Nox1 and Nox4 are not present in leucocytes, but are highly expressed in vascular cells and upregulated in vascular remodeling, such as that found in hypertension and atherosclerosis. This offers the opportunity to develop "vascular specific" NADPH oxidase inhibitors that do not compromise the essential physiological signaling and phagocytic function carried out by reactive oxygen and nitrogen molecules. Although many conventional antioxidants fail to significantly affect outcomes in cardiovascular disease, targeted inhibitors of NADPH oxidase that block the source of oxidative stress in the vasculature are more likely to prevent the deterioration of vascular function that leads to stroke and heart attack.
越来越多的证据表明,氧化应激,即活性氧和氮物种的过度产生,是多种心血管疾病的基础。动脉壁氧化应激的主要来源是NADPH氧化酶。这种存在于包括内皮细胞在内的血管细胞中的酶复合物,在生化结构和功能上与吞噬性白细胞中的酶复合物不同。关键的含黄素催化亚基Nox1和Nox4不存在于白细胞中,但在血管细胞中高度表达,并在血管重塑(如高血压和动脉粥样硬化中所见)中上调。这为开发“血管特异性”NADPH氧化酶抑制剂提供了机会,这些抑制剂不会损害活性氧和氮分子所执行的基本生理信号传导和吞噬功能。尽管许多传统抗氧化剂未能显著影响心血管疾病的治疗结果,但靶向抑制NADPH氧化酶以阻断血管系统中氧化应激来源的药物更有可能预防导致中风和心脏病发作的血管功能恶化。